SynthesisWorld journal of urology2025
The enduring role of PCNL in complex stone disease: a systematic review of four challenging cohorts.
Synthesis in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile advances in flexible ureteroscopes and disposable suction systems have led to questions about percutaneous nephrolithotomy’s (PCNL) role in stone management, these alternatives are often insufficient for complex cases. This review examines PCNL’s efficacy and safety in four difficult patient groups: those with urinary diversion, neuromuscular disorders, renal transplants, and congenital anomalies where less invasive modalities, including flexible ureteroscopy and extracorporeal shock wave lithotripsy (ESWL), are often insufficient.
methodsA systematic review was conducted according to PRISMA guidelines and registered in PROSPERO (CRD420251044426). PubMed and Cochrane Library databases were searched for studies no lower date limit, through December 31, 2024. Study selection and quality assessment (Newcastle-Ottawa Scale) were performed independently by multiple reviewers. The primary outcome was stone-free rate, while secondary outcomes included complication rates and clinical feasibility of PCNL in these patient groups.
resultsA total of 28 studies with 1,014 patients were included. PCNL was performed following failed ESWL or ureteroscopy (URS) in 18% of cases and often achieved complete clearance where previous modalities had failed. Across all subgroups, stone-free rates ranged from 48.7% to 100%, with highest outcomes in renal transplants (91.4%) and anomalies (84–92%). Complication rates varied (6.7–50%), reflecting anatomical complexity. Modified techniques such as Mini-PCNL enhanced feasibility in select cases.
conclusionPCNL remains the most effective option in complex stone cases where flexible ureteroscopy (fURS) or ESWL often fail, consistently achieving high clearance rates with acceptable morbidity in anatomically challenging patients. Rather than being replaced, PCNL continues to define the boundaries of what is possible in endourology’s most difficult scenarios.
Indexed as
Identifiers
41296114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.